Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia

    Research output: Contribution to journalReviewResearchpeer-review

  2. Antiplatelets after intracerebral haemorrhage: treat the patient, not the brain imaging

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Peripheral neuropathy in hereditary spastic paraplegia caused by REEP1 variants

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Ralf Reilmann
  • Andrew McGarry
  • Igor D Grachev
  • Juha-Matti Savola
  • Beth Borowsky
  • Eli Eyal
  • Nicholas Gross
  • Douglas Langbehn
  • Robin Schubert
  • Anna Teige Wickenberg
  • Spyros Papapetropoulos
  • Michael Hayden
  • Ferdinando Squitieri
  • Karl Kieburtz
  • G Bernhard Landwehrmeyer
  • European Huntington's Disease Network
  • Christina Vangsted-Hansen (Member of study group)
  • Lena Elisabeth Hjermind (Member of study group)
View graph of relations

BACKGROUND: Previous trials have shown that pridopidine might reduce motor impairment in patients with Huntington's disease. The aim of this study was to ascertain whether higher doses of pridopidine than previously tested reduce motor symptoms in a dose-dependent manner while maintaining acceptable safety and tolerability.

METHODS: PRIDE-HD was a randomised, placebo-controlled, phase 2, dose-ranging study in adults (aged ≥21 years) with Huntington's disease at outpatient clinics in 53 sites across 12 countries (Australia, Austria, Canada, Denmark, France, Germany, Italy, Poland, Russia, the Netherlands, the UK, and the USA). Eligible patients had clinical onset after age 18 years, 36 or more cytosine-adenine-guanine repeats in the huntingtin gene, motor symptoms (Unified Huntington's Disease Rating Scale total motor score [UHDRS-TMS] ≥25 points), and reduced independence (UHDRS independence score ≤90%). Patients were randomly assigned (1:1:1:1:1) with centralised interactive-response technology to receive one of four doses of pridopidine (45, 67·5, 90, or 112·5 mg) or placebo orally twice a day for 52 weeks. Randomisation was stratified within centres by neuroleptic drug use. The primary efficacy endpoint was change in the UHDRS-TMS from baseline to 26 weeks, which was assessed in all randomised patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment (full analysis set). Participants and investigators were masked to treatment assignment. This trial is registered with EudraCT (2013-001888-23) and (NCT02006472).

FINDINGS: Between Feb 13, 2014, and July 5, 2016, 408 patients were enrolled and randomly assigned to receive placebo (n=82) or pridopidine 45 mg (n=81), 67·5 mg (n=82), 90 mg (n=81), or 112·5 mg (n=82) twice daily for 26 weeks. The full analysis set included 397 patients (81 in the placebo group, 75 in the 45 mg group, 79 in the 67·5 mg group, 81 in the 90 mg group, and 81 in the 112·5 mg group). Pridopidine did not significantly change the UHDRS-TMS at 26 weeks compared with placebo at any dose. The most frequent adverse events across all groups were diarrhoea, vomiting, nasopharyngitis, falls, headache, insomnia, and anxiety. The most common treatment-related adverse events were insomnia, diarrhoea, nausea, and dizziness. Serious adverse events occurred in the pridopidine groups only and were most frequently falls (n=5), suicide attempt (n=4), suicidal ideation (n=3), head injury (n=3), and aspiration pneumonia (n=3). No new safety or tolerability concerns emerged in this study. One death in the pridopidine 112·5 mg group due to aspiration pneumonia was considered to be possibly related to the study drug.

INTERPRETATION: Pridopidine did not improve the UHDRS-TMS at week 26 compared with placebo and, thus, the results of secondary or tertiary analyses in previous trials were not replicated. A potentially strong placebo effect needs to be ruled out in future studies.

FUNDING: Teva Pharmaceutical Industries.

Original languageEnglish
JournalThe Lancet Neurology
Issue number2
Pages (from-to)165-176
Number of pages12
Publication statusPublished - Feb 2019

ID: 56391619